Neal K Lakdawala

List of Publications by Year
in descending order

71 papers	5,352 citations	126907 33 h-index	106344 65 g-index
73 all docs	73 docs citations	73 times ranked	5954 citing authors

#	Article	IF	Citations
1	The Road Not Yet Traveled: Distinction in Critical Care Cardiology through the Advanced Heart Failure and Transplant Cardiology Training Pathway. Journal of Cardiac Failure, 2022, 28, 339-342.	1.7	13
2	Association of Titin Variations With Late-Onset Dilated Cardiomyopathy. JAMA Cardiology, 2022, 7, 371.	6.1	18
3	The response to cardiac resynchronization therapy in <scp>LMNA</scp> cardiomyopathy. European Journal of Heart Failure, 2022, 24, 685-693.	7.1	7
4	Pregnancy and Progression of Cardiomyopathy in Women With LMNA Genotypeâ€Positive. Journal of the American Heart Association, 2022, 11, e024960.	3.7	3
5	Sexâ€Related Differences in Genetic Cardiomyopathies. Journal of the American Heart Association, 2022, 11, e024947.	3.7	18
6	2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders. Heart Rhythm, 2022, 19, e61-e120.	0.7	13
7	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	3.1	6
8	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003062.	3.6	38
9	Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy. Circulation, 2021, 143, 606-608.	1.6	109
10	Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	19
11	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics in Medicine, 2021, 23, 1281-1287.	2.4	11
12	Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know. European Heart Journal, 2021, 42, 2384-2396.	2.2	28
13	Contribution of Noncanonical Splice Variants toTTNTruncating Variant Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003389.	3.6	15
14	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1818-1824.	30.7	51
15	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
16	Separate and Unequal: Cardiovascular Medicine in Black Americans. Journal of the American Heart Association, 2021, 10, e022841.	3.7	1
17	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	2.2	43
18	Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment. Current Heart Failure Reports, 2021, 18, 264-273.	3.3	28

#	Article	IF	Citations
19	Cardiac Sarcoidosis: When and How to Treat Inflammation. Cardiac Failure Review, 2021, 7, e17.	3.0	18
20	418â€ƒTitin mutations and female sex characterize dilated cardiomyopathy in the elderly. European Heart Journal Supplements, 2021, 23, .	0.1	0
21	Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. Clinical Cardiology, 2020, 43, 43-49.	1.8	14
22	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 83.	6.1	60
23	Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 396-405.	3.6	47
24	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
25	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2020, 141, 1872-1884.	1.6	229
26	Expanding the clinical and genetic spectrum of ALPK3 variants: Phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants. American Heart Journal, 2020, 225, 108-119.	2.7	25
27	Second Hits in Dilated Cardiomyopathy. Current Cardiology Reports, 2020, 22, 8.	2.9	15
28	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction. Circulation, 2020, 141, 1371-1383.	1.6	108
29	Ventricular tachycardia in cardiolaminopathy: Characteristics and considerations for device programming. Heart Rhythm, 2020, 17, 1704-1710.	0.7	8
30	Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 75, 2649-2660.	2.8	176
31	Deletion of entire LMNA gene as a cause of cardiomyopathy. HeartRhythm Case Reports, 2020, 6, 395-397.	0.4	1
32	Cardiocutaneous Features of Autosomal Dominant Desmoplakin-Associated Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e003081.	3.6	7
33	Hypertrophic Cardiomyopathy as an Unexpected Mimic of Inducible Laryngeal Obstruction: The Case for Cardiopulmonary Exercise Testing in Otolaryngology. Journal of Voice, 2020, , .	1.5	0
34	Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents. Journal of the American College of Cardiology, 2019, 74, 346-358.	2.8	63
35	The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication. Molecular Genetics & Genomic Medicine, 2019, 7, e940.	1.2	13
36	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation, 2019, 140, 293-302.	1.6	131

#	Article	IF	Citations
37	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e008975.	2.6	54
38	Response by Ho et al to Letter Regarding Article, â€œGenotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)â€. Circulation, 2019, 139, 1559-1560.	1.6	4
39	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	3.9	96
40	Phenotypic Characterization of Individuals With Variants in Cardiovascular Genes in the Absence of a Primary Cardiovascular Indication for Testing. Circulation Genomic and Precision Medicine, 2019, 12, e002463.	3.6	3
41	Patients report more severe daily limitations than recognized by their physicians. Clinical Cardiology, 2019, 42, 1181-1188.	1.8	4
42	Response by Divakaran et al to Letter Regarding Article, â€œDiagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis: An Imaging-Histologic Correlation Study in Patients Undergoing Cardiac Transplantationâ€. Circulation: Cardiovascular Imaging, 2019, 12, e009622.	2.6	4
43	Spot Urine Sodium as Triage for Effective Diuretic Infusion in an Ambulatory Heart Failure Unit. Journal of Cardiac Failure, 2018, 24, 349-354.	1.7	44
44	The Lifespan of Genetic Testing. American Journal of Medicine, 2018, 131, 991-992.	1.5	0
45	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 1387-1398.	1.6	468
46	A Shocking Turn of Events. New England Journal of Medicine, 2018, 379, 1386-1387.	27.0	0
47	First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. American Heart Journal, 2018, 203, 95-100.	2.7	35
48	Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. European Heart Journal Cardiovascular Imaging, 2018, 19, 1109-1116.	1.2	31
49	A Shocking Turn of Events. New England Journal of Medicine, 2018, 378, 2225-2230.	27.0	2
50	Risk for hypertension crosses generations in the community: a multi-generational cohort study. European Heart Journal, 2017, 38, 2300-2308.	2.2	55
51	A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	62
52	Role of Genetic Testing in Inherited Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1153.	6.1	75
53	Intragastric balloon for management of morbid obesity in a candidate for heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 820-821.	0.6	9
54	Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham Heart Study. BMJ: British Medical Journal, 2017, 357, j1949.	2.3	59

#	Article	IF	Citations
55	Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart, 2016, 102, 1805-1812.	2.9	37
56	Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 2016, 133, 1901-1905.	1.6	41
57	Multicenter Experience With Catheter Ablation for Ventricular Tachycardia in Lamin A/C Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	85
58	Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. Journal of the American College of Cardiology, 2016, 68, 2299-2307.	2.8	215
59	Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy SarcomereÂMutation Carriers. JACC: Heart Failure, 2015, 3, 180-188.	4.1	137
60	Big data for a rare disease: Examining heart transplantation for left ventricular noncompaction in the United Network of Organ Sharing registry. Journal of Heart and Lung Transplantation, 2015, 34, 759-760.	0.6	4
61	Multimodality Imaging for the Assessment of Total Artificial Heart Function. Journal of the American College of Cardiology, 2014, 63, e7.	2.8	0
62	The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genetics in Medicine, 2014, 16, 601-608.	2.4	284
63	Using Genetic Testing to Guide Therapeutic Decisions in Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 387-396.	0.9	9
64	Dilated Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 228-237.	4.8	93
65	Subtle Abnormalities in Contractile Function Are an Early Manifestation of Sarcomere Mutations in Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2012, 5, 503-510.	5.1	68
66	Truncations of Titin Causing Dilated Cardiomyopathy. New England Journal of Medicine, 2012, 366, 619-628.	27.0	1,147
67	Genetic Testing for Dilated Cardiomyopathy in Clinical Practice. Journal of Cardiac Failure, 2012, 18, 296-303.	1.7	145
68	Electrocardiographic Features of Sarcomere Mutation Carriers With and Without Clinically Overt Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2011, 108, 1606-1613.	1.6	77
69	Dilated Cardiomyopathy With Conduction Disease and Arrhythmia. Circulation, 2010, 122, 527-534.	1.6	40
70	Familial Dilated Cardiomyopathy Caused by an Alpha-Tropomyosin Mutation. Journal of the American College of Cardiology, 2010, 55, 320-329.	2.8	104
71	Cascade testing for inherited cardiac conditions: Risk perception and screening after a negative genetic test result. Journal of Genetic Counseling, 0, , .	1.6	1